Cargando…

The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction

Finerenone is a novel non-steroidal mineralocorticoid receptor (MR) antagonist (MRA) with high binding affinity, high MR selectivity and a short plasma half-life. In two major endpoint-driven clinical trials in patients with chronic kidney disease and type 2 diabetes mellitus (FIDELIO-DKD and FIGARO...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kintscher, Ulrich, Edelmann, Frank
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10311906/ https://www.ncbi.nlm.nih.gov/pubmed/37386461 http://dx.doi.org/10.1186/s12933-023-01899-0

Ejemplares similares

Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction
por: Lima-Posada, Ixchel, et al.
Publicado: (2023)

Prognostic impact of mineralocorticoid receptor antagonist in patients with heart failure with preserved ejection fraction
por: Suzuki, Sho, et al.
Publicado: (2020)

Implication of Mineralocorticoid Receptor Antagonist Esaxerenone in Patients With Heart Failure With Preserved Ejection Fraction
por: Imamura, Teruhiko, et al.
Publicado: (2021)

Effects of Mineralocorticoid Receptor Antagonists in Early-Stage Heart Failure With Preserved Ejection Fraction
por: Kagami, Kazuki, et al.
Publicado: (2023)

The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone
por: Heinig, Roland, et al.
Publicado: (2023)

Incremental value of mineralocorticoid receptor antagonists in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan
por: Benini, Annachiara, et al.
Publicado: (2022)

Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease
por: Shah, Monarch, et al.
Publicado: (2023)

The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure: A systematic review and meta-analysis
por: Pei, Hui, et al.
Publicado: (2018)

Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction
por: Serenelli, Matteo, et al.
Publicado: (2020)

Comorbidities in heart failure with preserved ejection fraction
por: Deichl, Andrea, et al.
Publicado: (2022)

Finerenone: Questions and Answers—The Four Fundamental Arguments on the New-Born Promising Non-Steroidal Mineralocorticoid Receptor Antagonist
por: Di Lullo, Luca, et al.
Publicado: (2023)

Cardiovascular and Renal Outcomes with Finerenone, a Selective Mineralocorticoid Receptor Antagonist
por: Palanisamy, Srikanth, et al.
Publicado: (2022)

Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease
por: Kim, Dong-Lim, et al.
Publicado: (2023)

PSUN68 Finerenone for Primary Aldosteronism: A Novel Mineralocorticoid Receptor Antagonist
por: Aurora, John, et al.
Publicado: (2022)

Efficacy and Safety of Novel Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone in the Management of Diabetic Kidney Disease: A Meta-analysis
por: Dutta, Deep, et al.
Publicado: (2022)

Suppression of Tumourigenicity 2 in Heart Failure With Preserved Ejection Fraction
por: Zach, Veronika, et al.
Publicado: (2020)

The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury
por: Dutzmann, Jochen, et al.
Publicado: (2017)

Facts and numbers on epidemiology and pharmacological treatment of heart failure with preserved ejection fraction
por: Edelmann, Frank
Publicado: (2015)

Abstract 1: Efficacy and safety of novel non-steroidal mineralocorticoid receptor antagonist finerenone in the management of diabetic kidney disease: A meta-analysis
por: Dutta, Deep, et al.
Publicado: (2022)

Finerenone, a Non-Steroidal Mineralocorticoid Receptor Antagonist, Reduces Vascular Injury and Increases Regulatory T-Cells: Studies in Rodents with Diabetic and Neovascular Retinopathy
por: Jerome, Jack R., et al.
Publicado: (2023)

Correction: Incremental value of mineralocorticoid receptor antagonists in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan
Publicado: (2023)

Effects of mineralocorticoid receptor antagonists in patients with preserved ejection fraction: a meta-analysis of randomized clinical trials
por: Chen, Yanmei, et al.
Publicado: (2015)

Effect of Mineralocorticoid Receptor Antagonists on Cardiac Structure and Function in Patients With Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: A Meta‐Analysis and Systematic Review
por: Pandey, Ambarish, et al.
Publicado: (2015)

Effect of mineralocorticoid receptor antagonists on cardiac function in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials
por: Kapelios, Chris J., et al.
Publicado: (2019)

Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
por: Agarwal, Rajiv, et al.
Publicado: (2020)

Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2022)

Mineralocorticoid receptor blockade with finerenone improves heart function and exercise capacity in ovariectomized mice
por: Pieronne‐Deperrois, Marie, et al.
Publicado: (2021)

Non-steroidal mineralocorticoid receptor antagonist finerenone ameliorates mitochondrial dysfunction via PI3K/Akt/eNOS signaling pathway in diabetic tubulopathy
por: Yao, Lan, et al.
Publicado: (2023)

Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS‐HF and RALES
por: Yeoh, Su E., et al.
Publicado: (2021)

Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin
por: Aimo, Alberto, et al.
Publicado: (2022)

Heart failure with preserved ejection fraction
por: Rigolli, Marzia, et al.
Publicado: (2013)

Heart failure with preserved ejection fraction
por: ElGuindy, Ahmed, et al.
Publicado: (2012)

Heterogeneous Metabolic Response to Exercise Training in Heart Failure with Preserved Ejection Fraction
por: Bahls, Martin, et al.
Publicado: (2019)

SAT-LB106 Metabolic and Brown Adipose Tissue-Specific Effects of the Novel Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in a Mouse Model of Diet-Induced Obesity
por: Marzolla, Vincenzo, et al.
Publicado: (2020)

Mineralocorticoid receptor antagonism by finerenone is sufficient to improve function in preclinical muscular dystrophy
por: Lowe, Jeovanna, et al.
Publicado: (2020)

Mineralocorticoid receptor antagonist use following heart failure hospitalization
por: Duran, Jason M., et al.
Publicado: (2020)

Epigenetic remodeling in heart failure with preserved ejection fraction
por: Ambrosini, Samuele, et al.
Publicado: (2022)

Dose–Exposure–Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO-DKD
por: Goulooze, Sebastiaan Camiel, et al.
Publicado: (2022)

Biomarkers in heart failure with preserved ejection fraction
por: Meijers, W. C., et al.
Publicado: (2016)

Management of heart failure with preserved ejection fraction
por: Gard, Emma, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_85fu14vtrte3ph8ro5cv5k7n1c